MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stress

Kristyn Gumpper-Fedus a,1, Ki Ho Park a,1, Hanley Ma a, Xinyu Zhou a, Zehua Bian a, Karthikeyan Krishnamurthy a, Matthew Sermersheim a, Jingsong Zhou b, Tao Tan a, Lei Li c, Jianxun Liu c, Pei-Hui Lin a, Hua Zhu a,1,2, Jianjie Ma a,2,*

a The Ohio State University Wexner Medical Center, Department of Surgery, Columbus, OH, 43210, USA
b University of Texas at Arlington, Department of Kinesiology, Arlington, TX, 76109, USA
c Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China

A R T I C L E  I N F O

Keywords:
Cardioprotection
Mitophagy
Cell membrane repair
TRIM72
Myocardial infarction
Cardiolipin

A B S T R A C T

Ischemic injury to the heart induces mitochondrial dysfunction due to increasing oxidative stress. MG53, also known as TRIM72, is highly expressed in striated muscle, is secreted as a myokine after exercise, and is essential for repairing damaged plasma membrane of many tissues by interacting with the membrane lipid phosphatidylserine (PS). We hypothesized MG53 could preserve mitochondrial integrity after an ischemic event by binding to the mitochondrial-specific lipid, cardiolipin (CL), for mitochondrial protection to prevent mitophagy. Fluorescent imaging and Western blotting experiments showed recombinant human MG53 (rhMG53) translocated to the mitochondria after ischemic injury in vivo and in vitro. Fluorescent imaging indicated rhMG53 treatment reduced superoxide generation in ex vivo and in vitro models. Lipid-binding assay indicated MG53 binds to CL. Transfecting cardiomyocytes with the mitochondria-targeted mt-mKeima showed inhibition of mitophagy after MG53 treatment. Overall, we show that rhMG53 treatment may preserve cardiac function by preserving mitochondrial integrity in cardiomyocytes. These findings suggest MG53’s interactions with mitochondria could be an attractive avenue for developing MG53 as a targeted protein therapy for cardioprotection.

1. Introduction

Ischemic heart disease remains one of the top causes of mortality worldwide [1]. Ischemic/reperfusion injury like acute myocardial infarction (MI) causes a loss of healthy mitochondria from reactive oxygen species (ROS) release, inhibiting energy production and resulting in cardiomyocyte death [2,3]. Therapeutic approaches that preserve mitochondria integrity would be invaluable for improving survival after ischemic injury.

MG53, also known as TRIM72, is highly expressed in skeletal muscle [4] and can be secreted from skeletal muscle, where it acts as a myokine to repair other damaged tissues [5]. MG53’s membrane repair function is associated with changes in oxidative state inside the cell [4,6], and extracellular MG53 can target the exposed phosphatidylserine (PS) to facilitate the repair of injured tissues [7]. We have shown that mg53−/− mice are more susceptible to injury [4,8–10], and treatment with exogenous recombinant human MG53 (rhMG53) reduces damage and restores functions in tissues like the kidney [10], lung [5], and heart [11].

Previously, we have shown that exogenous [11] and endogenous [12] MG53 can preserve cardiac tissue morphology, ejection fraction, and fractional shortening after an ischemic event. However, these earlier studies focused on cardiac function and did not delve into the mechanisms protecting the cardiac tissue, such as maintaining mitochondrial processes that are susceptible to ischemic/reperfusion injury. MG53’s link to mitochondrial protection after such an event is unclear. We demonstrated that endogenous MG53 co-localized with mitochondria in skeletal muscles derived from mice fed with a high-fat diet [13]. Additionally, Chung et al. [14] found enrichment of endogenous
TRIM72 (MG53) in the mitochondria fraction of mouse hearts subjected to ischemic preconditioning, an experimental technique to induce resistance to a temporary lack of oxygen. While these studies show MG53 is essential for cell survival and a potential interaction of MG53 with the mitochondria, the mechanism behind MG53’s role in facilitating mitochondrial protection and how this may protect the heart after an ischemic event like MI remains unknown.

In this study, we test whether exogenous rhMG53 can either directly prevent oxidative stress-induced injury to mitochondria or indirectly preserve the pool of healthy mitochondria through the modulation of mitophagy. We found that MG53 can bind to cardiolipin (CL), a mitochondria-specific phospholipid, to prevent injury to the mitochondria. Furthermore, rhMG53 treatment mitigates the engulfment of mitochondria by the lysosome and reduces parkin localization to the mitochondria.

2. Methods

2.1. Porcine model of angioplasty-induced myocardial infarction

Chinese experimental miniature swine were provided by Beijing Experimental Animal Reproduction and Regulation Center (Grade II, Certificate No. Jing-030). All porcine experiments in this study were performed in accordance with China Academy of Chinese Medical Sciences Guide for Laboratory Animals that conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. According to established methods, experimental pigs underwent balloon inflation of the left anterior descending (LAD) coronary artery [11]. rhMG53 was administered at a 1 mg/kg dose immediately after experimental intervention through the jugular vein. Infarct size and location for histology samples were previously reported in Liu et al. [11].

2.2. Murine model of acute myocardial infarction

All murine experiments in this study were performed following The Ohio State University IACUC-approved protocols. The mg3/C–/– and wild-type littermate mice were used. Saline or 1 mg/kg rhMG53 dissolved in saline was injected via the tail vein 10 min prior to induction of MI via LAD coronary artery ligation as previously described [15]. Ischemia was maintained for 60 min and then released. After ischemia, the mouse recovered for 6 h before cardiac tissue collection for histology and immunofluorescent staining.

2.3. Neonatal cardiomyocyte isolation

Neonatal cardiomyocytes were isolated and pooled from six to ten 1–2 day old C57BL/6 mice. Animals were decapitated, hearts removed and washed into PBS (without Ca2+, Mg2+) with 20 mM BDM, atra excised, ventricles transferred to 250 μL isolation solution (HBSS (without Ca2+, Mg2+) with 0.0125% trypsin, 20 mM BDM) and then minced. After mincing hearts into small pieces (approximately 0.5–1 mm2 or smaller), minced hearts were transferred into a 50 mL conical tube containing 10 mL of the isolation solution (on ice) and incubated with gentle agitation at 4 °C for 1–2 h. After allowing the tissue fragments to sink to the bottom of the tube, the supernatant was removed, and 5 mL prewarmed digestion solution (L-15 medium with 20 mM BDM, 1 mg/mL Worthington collagenase type II) was added for a 5 min digestion with gentle agitation in 37 °C. The supernatant was then transferred to a new tube with an additional 4% FBS to stop the digestion. The heart fragment digestion was repeated 5 times. After collecting all the supernatant into 50 mL conical tube, it was passed through a 75 μm cell strainer and centrifuged at 1,000 rpm for 4 min. The resulting cell pellet was resuspended in 10 mL plating medium (65% DMEM, 19% M-199, 10% horse serum, 5% FBS, 1% penicillin/streptomycin) and added to a 10 cm cell culture dish for 1–3 h to remove highly adhesive fibroblasts and endothelial cells. After incubation, non-adherent cardiomyocytes from the 10 cm culture dish were collected and transferred to a sterile 15 mL conical tube. Approximately 1.5 × 105 cells/cm2 were then added to a Geltrex (Thermo Fisher, A1413301)-coated glass-bottom dish. The cells were left undisturbed in a cell culture incubator for 16–24 h to adhere and spread to the bottom. One day after plating, the plating medium was replaced with a maintenance medium (78% DMEM, 17% M-199, 4% horse serum, 1% penicillin/streptomycin) and cultured for additional 2–5 days.

2.4. Oxidative damage to neonatal cardiomyocytes

Neonatal cardiomyocytes were preincubated for 1 h with/without 10 μg/mL BSA or rhMG53, treated with 50 μM H2O2 in HBSS (in mM, 140 NaCl, 5 KCl, 0.5 MgCl2, 0.4 MgSO4, 1 CaCl2, 0.3 Na2HPO4, 0.4 KH2PO4, 6 Glucose, 20 HEPES, pH 7.2). TMRE (50 nM) was applied to the cells and images were collected for up to 60 min using a Nikon A1R confocal microscope with a 20x objective at 37 °C using a 561 nm excitation and 595 nm emission setting.

2.5. Oxidative damage to HL-1 cardiomyocytes

To generate a hypoxia/reoxygenation model of oxidative stress, we adapted the protocol for hypoxia, energy depletion, and acidosis (HEDA) from Åström-Olsson et al. [18]. HL-1 cardiomyocytes (Sigma, SCC065) were cultured at low passages (7–20) in supplemented Claycomb media according to established protocols [16,17]. Briefly, HL-1 cells in PBS pH 6.7 without glucose, Mg2+, or Ca2+ were placed in a sealed chamber gassed with 5% CO2, 1% O2, and 94% N2 to establish the HEDA environment for 24 h. Cells were reoxygenated in BSS (in mM, 140 NaCl, 2.8 KCl, 2 MgCl2, 1 CaCl2, 12 Glucose, 10 HEPES, pH 7.4) at 37 °C for 1 h. Control cells were incubated in BSS at 5% CO2 and 37 °C. For both conditions, cells were incubated with either 10 μg/mL BSA or rhMG53.

2.6. Confocal microscopy

Porcine and mouse tissue samples were embedded in paraffin, a cross-section of the heart was taken (5 μm thickness), and stained with antibodies against MG53 [4] and COX IV (Cell Signaling Technologies, 11967S). MG53 (633 nm), COX IV (546 nm), and DAPI (405 nm) stained antibodies against MG53 [4] and COX IV (Cell Signaling Technologies, 11967S) were subjected to 3 h of hypoxia and 2 h of reoxygenation. Live cell imaging of the dynamic changes of the mt-cpYFP fluorescence was conducted on a Zeiss 780 confocal microscope using Zen 2012 software (Zeiss). Co-localization of MG53 and COX IV was captured by fluorescence within the infarct area in the left ventricle and quantified using FIJI (ImageJ) [16]. HL-1 cells cultured on 35 mm glass-bottom dishes were incubated with 5 μM MitoSOX Red (Thermo Fisher, M36008) for 15 min at 37 °C, protected from light. Cells were rinsed and imaged in BSS. Images were collected with a Zeiss 780 confocal microscope with a 40x objective. The fluorescent integrated density for each cell was measured for analysis using FIJI.

2.7. Mitochondrial FLASH event measurement in isolated mouse cardiomyocytes

Transgenic mice expressing mt-cpYFP provided an assessment of the dynamic changes in superoxide signals from the mitochondria [17–22]. Cardiomyocytes were isolated from the mt-cpYFP transgenic mice following the protocol of Wang et al. [19]. The isolated cardiomyocytes were subjected to 3 h of hypoxia and 2 h of reoxygenation. Live cell imaging of the dynamic changes of the mt-cpYFP fluorescence was conducted on a Zeiss 510 confocal microscope at 40x at 1 frame/second by alternating excitation at 488 nm and collecting emission at 561 nm [19]. Flash events were analyzed using FIJI (ImageJ) [16].
2.8. Lipid binding assays

ELISA Snoopers® (Avanti Polar Lipids) lipid strips assessed rhMG53 binding capacity to PS and 18:1 CL. 8-well strips pre-coated with either lipid were incubated with increasing doses of rhMG53 (0, 0.3125, 0.625, 1.25, 2.5, 5, and 10 μg/mL). ELISAs were performed according to the manufacturer’s protocol. Signal was developed using Streptavidin-HRP detection antibody and TMB Substrate Reagent (BD OptEIA, 555214) and quantified using a Flex Station III plate reader. Monoclonal MG53 antibody (Clone 5259, generated by Dr. Hiroshi Takeshima, Kyoto, Japan) [4] conjugated to biotin was used for detection [4].

2.9. Mitophagy assay

pCHAC-mt-mKeima plasmid (Addgene plasmid #72342) [23] was packaged into lentivirus and infected HL-1 cells. Cells were imaged on a Nikon microscope in a 37°C heated and humidified chamber with 5% CO₂ in HL-1 media. Cells were counted, and 8 million cells were collected for fractionation. The remaining cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% NP-40, 0.5% SDS, and 0.5% deoxycholate) and supplemented with a cocktail of protease inhibitors (Sigma, S8820). The 8 million cells were centrifuged to collect the pellet and gently lysed using kit reagents. The supernatant cytosolic fraction was retained from the fractionation. The resulting mitochondrial pellet was lysed with 2% CHAPS in tris-buffered saline.

Protein membranes were developed by chemiluminescence using SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, 34096) on a ChemiDoc MP Imaging System (Bio-Rad). Lysates were separated on a 10% SDS-PAGE acrylamide gel and transferred to polyvinylidene fluoride membranes (PVDF) (Millipore). The blots were washed with Tris-buffered saline Tween-20 (TBS-T), blocked with 5% milk in TBS-T for 1 h. Blots were probed with antibodies against MG53 (Clone 914, generated by Dr. Hiroshi Takeshima, Kyoto, Japan), GAPDH (CST, 2118S), COX IV (CST, 11967S), p62/SQSTM1 (CST, 39749), and Parkin (CST, 4211). COX IV was used as a marker for mitochondria enrichment, while GAPDH marked the total and cytosolic fractions. Protein membranes were developed by chemiluminescence using SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, 34096) on a ChemiDoc MP Imaging System (Bio-Rad).

Mitochondria isolation was performed using the Mitochondria Isolation Kit for Cultured Cells (Thermo Fisher, 89874) following the manufacturer’s protocol. Briefly, HL-1 cells that underwent BSS or HEDA treatment with 10 μg/mL BSA or rhMG53 were trypsinized with TrypLE (Thermo Fisher, 12604021) and resuspended in 2 mL Claycomb media. Cells were counted, and 8 million cells were collected for fractionation. The remaining cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% NP-40, 0.5% SDS, and 0.5% deoxycholate) and supplemented with a cocktail of protease inhibitors (Sigma, S8820). The 8 million cells were centrifuged to collect the pellet and gently lysed using kit reagents. The supernatant cytosolic fraction was retained from the fractionation. The resulting mitochondrial pellet was lysed with 2% CHAPS in tris-buffered saline.

Protein membranes were developed by chemiluminescence using SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, 34096) on a ChemiDoc MP Imaging System (Bio-Rad). Lysates were separated on a 10% SDS-PAGE acrylamide gel and transferred to polyvinylidene fluoride membranes (PVDF) (Millipore). The blots were washed with Tris-buffered saline Tween-20 (TBS-T), blocked with 5% milk in TBS-T for 1 h. Blots were probed with antibodies against MG53 (Clone 914, generated by Dr. Hiroshi Takeshima, Kyoto, Japan), GAPDH (CST, 2118S), COX IV (CST, 11967S), p62/SQSTM1 (CST, 39749), and Parkin (CST, 4211). COX IV was used as a marker for mitochondria enrichment, while GAPDH marked the total and cytosolic fractions. Protein membranes were developed by chemiluminescence using SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, 34096) on a ChemiDoc MP Imaging System (Bio-Rad). Bio-Rad
Image Lab™ Version 6.0 software was used to calculate the band intensity for each western blot. Adjusted integrated density for each band was normalized to the appropriate loading control (COX IV for mitochondrial fraction and GAPDH for total/cytosolic fractions). The fold difference was calculated by dividing the normalized density of each condition to the control condition to compare between trials.

2.11. Statistical analysis

Data were analyzed by several statistical methods (e.g., paired or unpaired t-tests, ANOVA, etc.) using commercial Prism software (GraphPad Prism 9). Data are presented as means ± SD (unless otherwise noted). To compare multiple groups, one-way or two-way multifactorial analysis of variance (ANOVA) was used to determine statistical significance. Bartlett’s test was used to determine if the standard deviations were significantly different, necessitating the use of the Brown-Forsythe or Welch’s tests. Multiple testing corrections such as Dunnett’s T3 multiple comparisons test or Sidak’s multiple comparisons test were used. For 2-way ANOVAs, normality was tested using the Anderson-Darling and Kolmogorov-Smirnov tests. For all statistical tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

3. Results

3.1. rhMG53 targets mitochondria in mouse and pig models of myocardial infarction

MG53 predominately travels to the damaged cell membrane following skeletal muscle cell membrane damage. In healthy striated muscle, MG53 typically localizes to the t-tubules and cytosol. After an acute MI injury in mg53−/− mice treated with rhMG53, immunofluorescent staining revealed rhMG53 localization to the plasma membrane and intercalated discs (red), as expected (Fig. 1A). RhMG53 also co-localized with the mitochondria, indicated by an alignment of the red MG53 signal and the green COX IV signal (Fig. 1A).

We confirmed the dual plasma membrane and mitochondria localization in a porcine model of MI, which more closely mimics human heart damage. MG53 localizes mainly to the intercalated disks (Fig. 1B, top). However, MG53 shifts from the intercalated discs to localization with mitochondria after MI challenge (Fig. 1B, bottom). This shift to localization is highlighted in the cross-sectional fluorescent intensity analysis in Fig. 1C, where MG53’s changes from low intensity and no clear pattern in the sham treatment to a higher intensity that mimics the striated mitochondrial pattern after MI.

This localization is consistent with earlier studies in the heart by Chung et al. [14], who found enrichment of TRIM72/MG53 in mitochondria fraction derived from ischemia-reperfusion injured mouse heart. Moreover, the mitochondria localization pattern of rhMG53 in the porcine heart is consistent with our previous observation with skeletal muscle from high-fat diet treated mice [13].

3.2. Mitochondrial membrane integrity is maintained by rhMG53 after oxidative stress

Earlier studies on the protective effects of MG53 on the heart have shown that the presence of MG53 prevents the loss of the mitochondrial membrane potential [12]. We verified this in isolated neonatal cardiomyocytes treated with 50 μM H2O2 using TMRE as a readout for mitochondrial membrane potential (Fig. 2). rhMG53 treated preserved mitochondrial membrane integrity longer than BSA or no treatment.
3.3. Superoxide release in isolated cardiomyocytes after hypoxia/reoxygenation is inhibited by rhMG53

Therefore, we wanted to take this finding further and determine whether that also prevents the accumulation of mitochondrial-generated ROS after ischemic damage. We used the HL-1 cardiac muscle cell line derived from mice with the MitoSOX Red fluorescent indicator to measure rhMG53’s effect on mitochondria after oxidative damage. As shown in Fig. 3A, rhMG53 treatment under normoxic conditions did not alter ROS release from the mitochondria. However, we observed a significant increase in MitoSOX Red fluorescent intensity in cells that underwent hypoxia, energy depletion, and acidosis (HEDA) in the presence of BSA, indicating high concentrations of mitochondrial ROS in the cytoplasm that results from damaged mitochondria. Treating cells with rhMG53 during HEDA injury resulted in a significantly reduced MitoSOX Red fluorescent intensity like the control conditions (Fig. 3B). This suggests rhMG53 treatment prevents the generation of mitochondrial ROS in response to oxidative injury.

To ensure MG53’s prevention of mito-ROS accumulation after ischemic condition also occurs in true cardiomyocytes, we used an ex-vivo mouse model of mito-ROS analysis. Wang et al. [24] developed a novel indicator targeted to the mitochondrial matrix called circularly permuted yellow fluorescent protein (mt-cpYFP) that selectively fluoresce in the presence of O$_2$, the main ROS created by the electron transport chain in the mitochondria and is only released into the cytoplasm after damage to the mitochondria. We have recently used this tool to study mitochondrial ROS generation in the mouse model of amyotrophic lateral sclerosis (ALS), termed “mitoFlash” [17, 20–22]. In cardiomyocytes derived from the mt-cpYFP mice, we monitored mitochondrial superoxide generation after hypoxia/reoxygenation following our previous protocol [19]. Under basal conditions, mitoflash events are rare (Fig. 3C and D). However, subjecting the cardiomyocytes to hypoxia and reoxygenation significantly increases the frequency and area covered by superoxide flashes (Fig. 3C and D). When cardiomyocytes are treated with 2 μg/mL rhMG53 before hypoxia/reoxygenation, significantly fewer superoxide flashes occur covering a smaller area of the cardiomyocyte. This suggests rhMG53 treatment reduces superoxide production in the mitochondria after oxidative injury.

3.4. rhMG53 binds to cardiolipin to preserve mitochondria integrity under oxidative stress

To probe into how treatment of rhMG53 is preventing mitochondrial...
ROS generation, we performed subcellular fractionation of HL-1 cells with or without HEDA treatment to separate the cytosolic proteins from proteins associated with the mitochondria. As shown in Fig. 4A, MG53 was enriched in the mitochondria fraction after HEDA damage compared to the mitochondria fraction under normal conditions. Only GAPDH in the cytosolic lanes and COX IV in the mitochondrial lanes of the western blot indicate clear separation of the subcellular fractions.

Confocal imaging of cells that underwent normal or HEDA conditions and treated with rhMG53 confirmed the subcellular fractionation results (Fig. 4B). Cells that were not damaged did not have any rhMG53 entry into the cell. Conversely, damaged cells exhibited rhMG53 signal at both the plasma membrane (white arrows) and inside the cell surrounding the mitochondrial COX IV signal (yellow arrows).

We have previously shown that rhMG53 directly interacts with the phosphatidylserine (PS) on the plasma membrane to facilitate protection against injury to tissues by bringing lipid rafts to patch the damaged membrane [4]. However, unlike the plasma membrane, the mitochondrial membrane does not have PS. Thus, we hypothesized that MG53 might also interact with the phospholipid cardiolipin (CL) present on the mitochondria after damage to facilitate mitochondria membrane repair injury during oxidative stress. We used a lipid dot-blot assay to test whether rhMG53 can bind to CL. Fig. 4C demonstrates that MG53 binds to PS and CL, but not other typical membrane phospholipids. Quantitative lipid-based ELISA revealed dose-dependent binding of rhMG53 to PS and CL. N = 4. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 4. Oxidative stress leads to enrichment of rhMG53 at mitochondria in HL-1 cells by binding to the mitochondria lipid cardiolipin. (A) Representative western blots of 3 separate experiments of HL-1 cells treated with either 10 µg/mL BSA or rhMG53 underwent normoxia (BSS) or HEDA treatment and fractionated showing total protein (T), cytoplasmic protein (C), and mitochondrial protein (M). Purity of fractionation indicated with GAPDH and COX IV blotting. (B) rhMG53 tagged with Alexa647 binds to both the plasma membrane (white arrow) and localize to mitochondria (yellow arrow) of HL-1 after HEDA treatment. (C) rhMG53 binds to both phosphatidylserine (PS) and cardiolipin (CL). MG53 exhibits little or no binding to phosphatidylethanolamine (PE), phosphatidylcholine (PC), or phosphatidylglycerol (PG). (D) Quantitative lipid-based ELISA revealed dose-dependent binding of rhMG53 to PS and CL. N = 4. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

ROS generation, we performed subcellular fractionation of HL-1 cells with or without HEDA treatment to separate the cytosolic proteins from proteins associated with the mitochondria. As shown in Fig. 4A, MG53 was enriched in the mitochondria fraction after HEDA damage compared to the mitochondria fraction under normal conditions. Only GAPDH in the cytosolic lanes and COX IV in the mitochondrial lanes of the western blot indicate clear separation of the subcellular fractions.

Confocal imaging of cells that underwent normal or HEDA conditions and treated with rhMG53 confirmed the subcellular fractionation results (Fig. 4B). Cells that were not damaged did not have any rhMG53 entry into the cell. Conversely, damaged cells exhibited rhMG53 signal at both the plasma membrane (white arrows) and inside the cell surrounding the mitochondrial COX IV signal (yellow arrows).
3.5. rhMG53 prevents engulfment of mitochondria by lysosome after HEDA

Cells undergo mitophagy to degrade damaged mitochondria to preserve a pool of healthy mitochondria. HL-1 cells were infected with lentivirus carrying a mitochondrial-tagged keima fluorescent protein, mt-keima, to determine how MG53 might be involved in mitophagy. This tag has a fluorescent emission shift when pH changes from 3 to 8; fluorescing green at a neutral pH like the cytoplasm, shifting to red under acidic pH, similar to that found in the lysosome [23].

Fig. 5A and B reveals HL-1 cells pre-treated with BSA, which underwent oxidative damage, showed a substantial shift towards red fluorescence, an indicator of mitochondria in the acidic lysosome compartments. Treatment with rhMG53 prevents this shift, with mitochondria maintaining their bright green fluorescence. This suggests that treating cells with rhMG53 reduces mitophagy by the lysosome for degradation. We verified this by performing another cell fractionation and probing for parkin and p62. We found that treating cells with rhMG53 during HEDA reduced the amount of parkin within the mitochondrial fraction compared to the HEDA group treated with BSA (p = 0.0082) (Fig. 5C and D). Staining for p62 revealed rhMG53 treatment under control conditions increased p62 expression compared to BSA treatment (p = 0.0055). However, we saw no difference in p62 localization to the mitochondrial fraction after HEDA-induced oxidative stress. Upregulation of p62 in the total lysate regardless of BSA or rhMG53 treatment indicated HEDA induced the autophagic processes.

4. Discussion

Discovering tissue preservation methods after ischemic events like a heart attack is essential to improving survival, and maintaining a healthy mitochondria population after ischemic insult is essential for cell and tissue function. We have previously described how MG53, either endogenous or exogenous, can protect cells and tissue from ischemic injury by fixing damage to the plasma membrane [9–12,25,26]. Additionally, Chung et al. showed that endogenous MG53 was elevated in the mitochondria fraction of mouse hearts after ischemia in cardiomyocytes [14]. This study shows that exogenous rhMG53 can improve cardiomyocyte survival by preserving mitochondrial health after ischemic injury.

During ischemic/reperfusion injury, mitochondria in cardiomyocytes are severely damaged from elevated oxidative stress, resulting in excessive mitochondrial ROS production and mitophagy [27,28]. Mitophagy is a specialized form of autophagy that targets damaged mitochondria through increased Parkin signal on the outer mitochondrial membrane to recruit p62/LC3 complexes [29]. Through several models of oxidative stress including hypoxia/reoxygenation and hydrogen peroxide treatments in vitro and an acute MI model in vivo, we showed exogenous rhMG53 co-localized to the mitochondria to preserve mitochondria integrity. rhMG53 treatment maintained the...
mitochondrial membrane potential and reduced mitochondrial-associated ROS leak into the cytoplasm in cultured HL-1 cells and primary adult mouse cardiomyocytes. This resulted in reduced parkin localization at the mitochondria, indicating a reduction in mitophagy after oxidative stress.

Several recent studies have questioned the safety of rhGM53 application as a therapeutic agent [34,35]. We recently showed that sustained overexpression of MG53 does not alter metabolism while increasing regenerative capacity [5,36]. In this study, exogenous rhMG53 to cells does not alter mitochondrial ROS production under basal conditions, further supporting the safety of rhMG53 treatment. However, there was increased p62 expression when rhMG53 was added under basal conditions, suggesting there may be an increase in autophagy. Future studies will be required to determine whether this increase is a clinical concern when attempting to use rhMG53 to preserve cardiomyocytes after ischemic/reperfusion injury.

Overall, this study provides a novel mechanism behind how rhMG53 treatment may be a clinically relevant strategy for reducing cardiomyocyte injury and maintaining cardiac function in patients after ischemic injury. Although we show preservation of mitochondrial membrane potential, reduction in mitochondrial ROS production, and a decrease in mitophagy in cardiomyocytes using several methods of oxidative stress, this study is limited by a lack of mitochondrial function, which would further elucidate MG53’s effects preserving mitochondria after ischemic/reperfusion injury. Additionally, further studies on the timing of rhMG53 application for preserving tissue function will be required. Understanding MG53’s interactions with mitochondria could be an attractive avenue for developing MG53 as a targeted protein therapy for cardioprotection and potentially other regenerative medicine applications.

Sources of funding
This work was supported by NIH grants awarded to JM, PL and JZ, by American Heart Association Grant #19TPA34850169 to HZ, and partially supported by American Heart Association Grant #18PRE34030430 and the National Center for Advancing Translational Sciences TL-1 fellowship TL1TR002735 awarded to KGF.

Declaration of competing interest
JM is a founder of TRIM-edicine, Inc., a university spin-off biotechnology company that develops MG53 for regenerative medicine application. Intellectual properties related to MG53 were maintained by Rutgers University and the Ohio State University.

References
[1] A.N. Newbar, et al., Mortality from ischemic heart disease, Circ. Cardiovasc. Qual. Outcomes 12 (6) (2019), e005575.